<DOC>
	<DOCNO>NCT01189084</DOCNO>
	<brief_summary>The purpose observational study determine whether vaccine ( UB 311 ) , target N-terminal amino acid ( 1-14 ) amyloid beta peptide , long-term immunogenicity efficacy individual diagnose mild moderate Alzheimer 's disease ( AD ) previously receive UB 311-treatment . Amyloid beta select target antigen base support evidence hypothesis place accumulation amyloid beta initiate step AD .</brief_summary>
	<brief_title>Observational Study Monitor Long-term Immunogenicity Efficacy UB 311 Vaccine Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Individuals mild moderate Alzheimer 's disease receive three ( 3 ) injection UB 311 initial Phase I V118AD trial Individuals Alzheimer 's disease currently prohibit medication , severe uncontrolled systemic disease , unable unwilling comply study protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>amyloid beta</keyword>
	<keyword>vaccine</keyword>
</DOC>